Gold prices fall as geopolitical tensions ease; U.S. CPI looms
MARLBOROUGH, MA - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company with a market capitalization of $11.85 million, today announced significant executive team changes as part of its strategic efforts to advance its INTASYL siRNA technology platform, which is currently being developed for the treatment of cancer.
Robert Infarinato, with a 30-year background in finance and accounting leadership, has been named the new VP, Strategic Development, effective June 9, 2025. Infarinato will transition from his role as Chief Financial Officer to focus on strategic business development initiatives, particularly exploring potential applications of the INTASYL siRNA portfolio. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 10.58, indicating robust short-term financial stability. His previous experience includes leadership positions in various organizations, including serving as Chairman of the Board of Trustees for Abington Health and as executive Vice President and CFO of an international service company.
Concurrently, Lisa Carson has been appointed VP, Finance and Administration. Carson, who joined Phio in May 2025, brings over 20 years of finance and accounting experience, including her recent role as VP, Finance and Controller at Prelude Therapeutics, where she played a key role in the company’s IPO and expansion.
Phio’s CEO and President, Robert Bitterman, expressed his pleasure in announcing the appointments, emphasizing the company’s commitment to gaining greater awareness of the potential applications in their INTASYL siRNA portfolio.
The company’s lead clinical program, PH-762, is an INTASYL compound designed to silence the PD-1 gene, a target in various forms of skin cancer. Positive interim safety and efficacy results have been reported in the ongoing Phase 1b clinical trial for the treatment of skin cancer, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The stock has shown strong momentum recently, with InvestingPro data showing a 23% return over the past week and a 36.67% year-to-date gain. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics for PHIO.
This strategic initiative and the executive appointments underscore Phio’s dedication to their INTASYL technology and its potential applications in immuno-oncology therapeutics.
Investors and interested parties are reminded that this article is based on a press release statement from Phio Pharmaceuticals Corp. and should consider the forward-looking nature of the company’s statements, which are subject to risks and uncertainties outlined in their filings with the SEC. The company’s next earnings report is expected on August 12, 2025, with analysts projecting improved profitability for the fiscal year 2025.
In other recent news, Phio Pharmaceuticals has reported positive outcomes from its ongoing Phase 1b clinical trial for its siRNA-based therapy, PH-762, targeting skin cancer. The trial results revealed that two out of three patients with cutaneous squamous cell carcinoma achieved complete tumor clearance, while the third patient showed less than 50% clearance. No serious adverse effects have been reported, and the Safety Monitoring Committee has approved moving to a higher dose for further testing. Phio’s INTASYL technology, which underpins PH-762, aims to enhance immune response by silencing the PD-1 gene, a common target in cancer treatment.
In addition to clinical progress, H.C. Wainwright has initiated coverage of Phio Pharmaceuticals with a Buy rating, setting a price target of $14.00, citing the innovative approach of PH-762. The firm also reaffirmed its Buy rating with a $4.00 price target following Phio’s recent financial disclosures, which included promising data from the trial. The analysts suggest that updates on PH-762’s efficacy, expected in late 2025, could impact the stock positively. Phio Pharmaceuticals continues to advance the trial with the fourth cohort’s enrollment underway, aiming to complete this phase by the third quarter of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.